GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

What Are the Serious Stem Cell Therapy Risks?

Serious stem cell therapy risks include life-threatening infection, graft-versus-host disease, organ damage, abnormal tissue growth or tumors, severe vision loss, pulmonary embolism, and death. These risks do not apply equally to every treatment. Blood stem cell transplantation has a different risk profile from an unproven injection into a knee, eye, spine, or vein. Delaying effective care for an unproven treatment can also cause harm. Stem cell transplant Important patient and consumer information about regenerative medicine therapies

Here, “serious” means life-threatening harm, hospitalization, lasting disability, or major organ injury. To assess an offer, identify the exact cells, product, dose, route, and purpose. Neither “your own cells” nor a regulatory filing proves that a treatment is safe or effective. There is no single complication percentage that describes all treatments sold under the stem cell label.

What Are the Serious Stem Cell Therapy Risks?

Why the treatment type matters

A hematopoietic stem cell transplant (HSCT) restores blood-forming cells after conditioning treatment, often high-dose chemotherapy with or without radiation. It is established care for selected blood cancers and blood disorders. An allogeneic transplant uses donor cells; an autologous transplant uses the patient’s own cells. Conditioning, immune suppression, and donor immune cells account for many serious complications. Reduced-intensity regimens also exist, so not every transplant involves the same exposure. Stem cell transplant

Private-clinic services may instead involve adipose-derived cells, products labeled mesenchymal stem or stromal cells (MSCs), or other preparations. A supervised clinical trial, an approved product used for its authorized indication, and a private service without approval for that use are not interchangeable. Evidence must match the product and procedure being offered. The FDA’s warnings about unapproved regenerative products include serious harm from both patient-derived and donor-derived material. Important patient and consumer information about regenerative medicine therapies

Can stem cell therapy be fatal?

Yes. In HSCT, severe infection, graft-versus-host disease, and treatment-related organ damage can be life-threatening. The potential benefit may still justify these risks for a patient with a serious blood disease; that decision requires a transplant-specific assessment rather than a clinic’s general “success rate.” Stem cell transplant

Deaths have also prompted action outside conventional transplantation. On March 13, 2026, Japan’s Ministry of Health, Labour and Welfare (MHLW) issued an emergency order after a foreign patient deteriorated during administration of autologous adipose-derived mesenchymal stem cells for chronic pain at a Tokyo clinic. The patient had cardiopulmonary arrest in the ambulance and was confirmed dead at the receiving hospital. The cause was not established when the order was issued. MHLW ordered temporary suspension of the plan and related provision and manufacturing activities involving similarly manufactured preparations. Newpage_71555

This was a reported death following deterioration during treatment, not proof that the cells caused it. The order supplies neither a general death rate nor a basis for judging every Japanese clinic.

Severe infection and sepsis

Contaminated products

Contaminated material can introduce bacteria into the bloodstream, a joint, or tissues around the spine. In a 2018 U.S. outbreak, 12 patients developed infections after receiving unapproved umbilical cord blood-derived products. All were hospitalized; one patient’s initial stay for a spinal infection lasted 58 days. No deaths were reported. Investigators found bacteria in unopened vials, indicating contamination before distribution. The infections included bloodstream infections, joint infections, and epidural abscesses. Mm6750a5.htm

These 12 cases describe one outbreak, not an infection rate for all cell therapies. Ask which release tests were performed on the actual batch and what happens when a batch fails. A statement that a facility is registered does not establish product approval or sterility.

Weakened immunity after transplantation

HSCT creates a different infection risk through conditioning and immune suppression. According to the National Cancer Institute (NCI), full immune recovery can take several months after an autologous transplant and one to two years after an allogeneic or identical-twin transplant. A normal blood count does not necessarily mean immunity has fully recovered. These timelines concern blood stem cell transplantation, not a routine recovery period for clinic MSC injections. Stem cell transplant

Graft-versus-host disease and immune reactions

Graft-versus-host disease (GVHD) occurs when donor immune cells attack the recipient’s tissues. It can damage the skin, liver, intestines, and other organs after allogeneic HSCT. It may be acute or chronic, and treatment can require steroids or other immune-suppressing drugs. Stem cell transplant

GVHD is not a blanket risk of every donor-derived cell product, and it should not be presented as an expected complication of an autologous knee injection. Other inflammatory or immune reactions remain possible with unapproved products, including those made from a patient’s own cells. Important patient and consumer information about regenerative medicine therapies

Organ damage and long-term transplant effects

High-dose conditioning can injure healthy tissue as well as cancer cells. NCI lists liver, kidney, lung, and heart damage, infertility, cataracts, secondary cancers, and bone or muscle weakness among possible long-term problems after transplantation. Bleeding and increased infection risk are important early concerns. In autologous cancer transplants, there is also a small risk of returning cancer cells collected with the graft. Stem cell transplant

These complications belong in transplant consent discussions, including fertility planning before treatment. They are not evidence that every injection sold as stem cell therapy has the same organ-toxicity profile. Conversely, avoiding chemotherapy does not establish that an unproven cell injection is safe.

Tumors and abnormal tissue growth

The FDA identifies tumor formation, excessive growth, and cells developing into unintended tissue as safety concerns for unapproved regenerative products. The relevant questions are what cells the preparation contains, how their identity is checked, and what human follow-up exists for that product and route. Important patient and consumer information about regenerative medicine therapies

A 2016 case report described a 66-year-old man who developed an abnormal glioproliferative growth involving the spinal cord and thecal sac after stem cell interventions at commercial clinics abroad. The lesion consisted predominantly of non-host cells. He developed progressive lower back pain, paraplegia, and urinary incontinence. This is a documented human case of serious abnormal growth, not a complication percentage or evidence that all stem cell products cause cancer. 27331440

Blindness after eye injections

A 2017 case series described three patients with age-related macular degeneration who developed severe bilateral vision loss after intravitreal injections of autologous adipose tissue-derived “stem cells” at one U.S. clinic. Before injection, visual acuity ranged from 20/30 to 20/200; after one year, it ranged from 20/200 to no light perception. Complications included elevated eye pressure, retinal hemorrhage, retinal detachment, and lens dislocation. PMC5551890

The authors reported that all three patients paid for the procedure and that their consent forms did not mention a clinical trial, although the clinic was linked to a trial listing. A registry entry is not proof that a patient received treatment within an authorized trial, or that the treatment works. This series concerns a specific unproven cell preparation; it should not be confused with established eye injections using other medicines. PMC5551890

Pulmonary embolism after intravenous delivery

Pulmonary embolism is a blockage in a pulmonary artery. A 2013 report described three family members with multiple pulmonary emboli after repeated intravenous infusions of autologous adipose tissue-derived cells. The son received three infusions for a cervical disc problem; his parents received five for knee osteoarthritis. The report also described lung infarction, meaning damage from interrupted blood supply. PMC3743204

The son received anticoagulant treatment for a month before it was stopped because of blood in his urine; his parents were observed without anticoagulation. Follow-up CT at three months showed that the emboli were no longer detectable. This does not mean embolism is harmless or should be left untreated. The authors suspected a connection to the infusions, but this small series cannot establish incidence or prove the mechanism in every case. PMC3743204

Treatment failure and delayed care

The FDA lists “failure of the therapy to work as anticipated when approved treatments are available” among the safety concerns for unapproved regenerative products. Important patient and consumer information about regenerative medicine therapies

A treatment can cause harm without an immediate injection complication if it replaces effective care. Ask your specialist what could be lost by delaying the recommended medication, rehabilitation, surgery, or diagnostic workup. The comparison should be with appropriate care for your condition, not simply with “doing nothing.” Do not stop prescribed treatment on the advice of a sales consultation.

Which risks apply to your treatment?

Treatment setting Serious risks to discuss Evidence you need
Allogeneic HSCT GVHD, severe infection, bleeding, organ toxicity, infertility, secondary cancers, and treatment-related death Transplant-center estimates matched to your disease, donor, conditioning, and health
Autologous HSCT Severe infection, bleeding, organ toxicity, infertility, and secondary cancers Risks of the conditioning regimen and your prior treatment; donor GVHD is not the relevant comparison
Approved regenerative cell product The adverse reactions and uncertainties in that product’s official information The named product’s authorized indication, route, dose, warnings, and follow-up requirements
Experimental or unapproved clinic intervention Product- and route-specific infection, immune reactions, abnormal growth, eye injury, embolism, or delayed care Human safety data for the actual preparation and procedure, plus its regulatory and research status

A knee injection and an intravenous infusion offered for knee pain are different procedures. Likewise, an approved product for a narrow indication does not validate another clinic’s cell mixture. Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) publishes product-specific review and approval records; the exact record must match the treatment being discussed. 0004

How common are serious complications?

The sources above do not support a single risk percentage across stem cell treatments. A case report shows that an event occurred; it does not show how often it happens. An outbreak count also lacks a usable denominator for other products and clinics.

If a provider says a procedure is “99% safe,” ask how many people received the exact product, how serious events were defined, how long patients were followed, and how many were lost to follow-up. For HSCT, ask the transplant center for outcomes relevant to your diagnosis and regimen. For a clinic product without adequate human data, the honest answer may be that the serious-complication rate is unknown.

What Japan’s safety filings do and do not show

Japan’s Act on the Safety of Regenerative Medicine provides a framework for provision plans and safety reporting for interventions within its scope. Filing a plan is not marketing approval and does not establish efficacy. Product approval follows a separate regulatory pathway. Index 0004

On April 21, 2026, MHLW issued an emergency order concerning a Fukuoka clinic. The order disclosed that at least five patients treated for chronic pain on May 12 or 13, 2023, developed chills, fever, nausea, or other symptoms; at least one later needed inpatient care. These were historical events disclosed in a 2026 order, not five newly documented 2026 treatment events. The ministry found failures to report and investigate the events and described a manufacturer-led arrangement that compromised the clinic’s independent eligibility and dosing decisions. Newpage_72690

The March and April orders concern specific plans and manufacturing arrangements, not all Japanese regenerative medicine. They show why a filed plan cannot replace safety monitoring or independent medical judgment. Request the plan number, cell-processing facility, product details, and approval status; the site’s explanation of stem cell therapy safety in Japan can help identify the different documents, but the official record is the evidence.

Symptoms that need prompt medical attention

After HSCT, contact your care team immediately for a high temperature, shivering, or other signs of infection. NHS transplant guidance also calls for urgent contact for a painful, swollen limb, sudden breathlessness, sharp chest pain, coughing blood, or difficulty breathing. Follow your transplant team’s own emergency instructions. Complications

After any cell procedure, seek emergency care for severe breathing difficulty or chest pain, sudden vision loss, or new leg weakness or loss of bladder control after a spinal procedure. The eye and spinal reports illustrate why these symptoms cannot be dismissed as routine recovery. Call local emergency services when symptoms are severe; do not wait for the clinic to reopen. Tell the treating clinician what you received, when, where, and by which route. PMC5551890 27331440

Check the offer before consenting

Ask a qualified clinician to review your diagnosis, organ function, infections, medicines, prior treatments, and the proposed protocol’s eligibility criteria. These are matters for individual assessment, not a universal online clearance checklist. If you will travel home after treatment, agree on who will provide follow-up and manage a complication away from the treating clinic.

Ask for What to check
Product and procedure Cell source and identity, product name, dose, route, number of administrations, and whether any other substances are included
Human evidence Your disease and stage, the actual product and route, study phase, sample size, comparator, endpoints, follow-up, and serious adverse events
Regulatory documents Whether the document is a product approval, a provision plan, or a research record; which indication and procedure it actually covers
Manufacturing records Where the cells are processed, batch identification, release tests, results, and the response to a failed batch
Rescue and follow-up plan A named medical contact, after-hours access, receiving hospital, scheduled follow-up, and responsibility for complication costs
Alternatives Established care, the consequences of delay, and the plan if the cell treatment does not help

For example, if you are offered intravenous fat-derived cells for knee pain, do not accept a study of injections into the knee as proof that the infusion is safe. Check whether the cells, processing, dose, route, and follow-up match the offer.

The evidence in this guide comes from published clinical reports and public regulatory documents, not personal treatment experience. No individualized safety assessment can be made from those reports alone. Take the documents to a specialist who has no financial interest in the proposed treatment.

For questions about treatment information and documents provided on this site, contact the support team. An inquiry is not medical clearance or an independent safety assessment.

Ask about treatment documents

Bottom line

The serious risks depend on what is given and how: donor blood transplantation raises GVHD and conditioning-related concerns, contaminated products can cause severe infection, eye injections can cause blindness, and intravenous cell interventions have been followed by pulmonary embolism. The documented cases establish reasons for caution, not a universal complication rate.

Before consenting, you should be able to identify the product, route, relevant human evidence, regulatory status, and plan for complications. If those details are missing, the uncertainty itself belongs in the decision.

This article provides general education, not medical clearance. Do not stop or delay established treatment without discussing the consequences with your treating specialist.

Sources

Sources were checked on October 24, 2026, with selected reports and transplant guidance rechecked on October 27, 2026. Regulatory orders describe findings at the time they were issued; they do not establish a clinic’s current operating status.

  1. National Cancer Institute. Stem Cell Transplants in Cancer Treatment. United States. Rechecked October 27, 2026.
  2. U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. United States. Checked October 24, 2026; used for safety warnings, not a current list of approvals.
  3. Ministry of Health, Labour and Welfare. Emergency order under the Act on the Safety of Regenerative Medicine. Japan, March 13, 2026. Japanese; key facts translated. Rechecked October 27, 2026.
  4. Perkins KM, et al. Infections after receipt of bacterially contaminated umbilical cord blood-derived products. MMWR. 2018;67:1397–1399. United States. Rechecked October 27, 2026.
  5. Berkowitz AL, et al. Glioproliferative Lesion of the Spinal Cord as a Complication of “Stem-Cell Tourism”. N Engl J Med. 2016;375:196–198. Single case report. Checked October 24, 2026.
  6. Kuriyan AE, et al. Vision Loss after Intravitreal Injection of Autologous “Stem Cells” for AMD. N Engl J Med. 2017;376:1047–1053. United States; three-patient case series. Full text rechecked October 27, 2026.
  7. Jung JW, et al. Familial occurrence of pulmonary embolism after intravenous, adipose tissue-derived stem cell therapy. Yonsei Med J. 2013;54:1293–1296. Report by South Korean clinicians; three family members. Full text rechecked October 27, 2026.
  8. Pharmaceuticals and Medical Devices Agency. Review Reports: Regenerative Medical Products. Japan. Checked October 24, 2026.
  9. Ministry of Health, Labour and Welfare. Regenerative medicine, cell medicine, and gene therapy. Japan; regulatory framework. Checked October 24, 2026.
  10. Ministry of Health, Labour and Welfare. Emergency order under the Act on the Safety of Regenerative Medicine. Japan, April 21, 2026; includes adverse events following treatment in May 2023. Japanese; key facts translated. Rechecked October 27, 2026.
  11. NHS. Complications of a stem cell or bone marrow transplant. United Kingdom. Reviewed May 7, 2026; accessed October 27, 2026. Used for transplant-specific urgent-contact advice.